Advances in research based on antibody-cell conjugation

Area of Science:

• Biotechnology
• Immunotherapy
• Cellular Medicine

Background:

• Antibody-cell conjugation (ACC) is an emerging field in medicine and biotechnology.
• It involves linking immune cells, such as natural killer (NK) cells and cytokine-induced killer (CIK) cells, with monoclonal antibodies via linkers.

Purpose of the Study:

• To review current methods for constructing antibody-cell conjugates (ACC).
• To identify challenges and future directions in ACC technology development.
• To highlight ACC's potential in treating hematologic and solid tumors.

Main Methods:

• ACC technology directly modifies cell surfaces using specific antibodies.
• A simple and effective chemical coupling method is employed.
• This process endows cells with novel, targeted functions.

Main Results:

• ACC technology enables the development of cell therapies with enhanced specificity.
• The approach has shown promise in preclinical and clinical applications for cancer treatment.
• Review of construction methods reveals diverse strategies and ongoing optimization.

Conclusions:

• ACC represents a significant advancement in cell therapy, offering a versatile platform for targeted treatment.
• Further research into construction methods and clinical applications is warranted.
• ACC technology holds substantial promise for overcoming limitations in current cancer therapies.